Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

The phase 1‐2 study CO‐338‐010 (Study 10; NCT01482715) is evaluating single‐agent rucaparib, a poly(ADP‐ribose) polymerase inhibitor, administered orally to patients with an advanced solid tumor. In the dose escalation phase (Part 1), we characterized the single‐dose and steady‐state pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585632/
https://www.ncbi.nlm.nih.gov/pubmed/29799676
http://dx.doi.org/10.1002/cpdd.575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585632/
https://www.ncbi.nlm.nih.gov/pubmed/29799676
http://dx.doi.org/10.1002/cpdd.575

Ejemplares similares